MYC RNAi-Pt Combination Nanotherapy for Metastatic Prostate Cancer Treatment

Abstract

The main objective of this project is to develop an innovative nanotherapy modality by combining platinum (Pt) chemotherapy and MYC targeting RNA interference (RNAi) for more effective treatment of metastatic prostate cancer (PCa). Over the entire period of this project,we made significant accomplishments in each of the proposed tasks. We successfully developed, characterized, and optimized a reduction responsive nanoparticle (NP) platform for effective delivery of siRNA and cisplatin prodrug. The siMYC NPs and siMYC-Pt NPs wereextensively tested in vitro using different PCa cell lines including Pt-resistant cells, and the combination nanotherapy showed potent antitumorefficacy in subcutaneously xenografted PCa mouse model without obvious in vivo toxicities.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2019
Accession Number
AD1090657

Entities

People

  • Angelo De Marzo
  • Charles J Bieberich
  • Jinjun Shi
  • Omid C. Farokhzad
  • Srinivasan Yegnasubramanian

Organizations

  • Johns Hopkins School of Medicine
  • University of Maryland, Baltimore County

Tags

DTIC Thesaurus Topics

  • Alkenes
  • Biomedical And Dental Materials
  • Cardiovascular Physiological Processes
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Cellular Structures
  • Chemical Synthesis
  • Chemistry
  • Genetics
  • Health Services
  • Lymphatic System
  • Materials Science
  • Medical Personnel
  • Nanoparticles
  • Neoplasms
  • Organic Chemistry
  • Polymer Chemistry
  • Polymeric Films
  • Prostate Cancer
  • Proteins
  • Students
  • Therapy
  • Tissues

Readers

  • Aerial Delivery - Logistics and Supply Chain Management.
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech